STOCK TITAN

[Form 4] PROCTER & GAMBLE Co Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Jennifer L. Davis, listed as CEO - Health Care at Procter & Gamble (PG), reported transactions dated 10/01/2025. The Form 4 shows a disposition of 64,990.9326 shares of common stock and an indirect holding of 15,535.3029 shares held by a retirement plan trustee. The filing also reports an acquisition of 68,869 stock options at an exercise price of $153.18; those options are listed as exercisable beginning 09/29/2028 with an expiration date of 10/01/2035.

The form includes an explanatory note that the indirect amount reflects an adjustment to the participant service trust through 09/30/2025. The document is signed on behalf of Ms. Davis by an attorney-in-fact on 10/02/2025. All items reported are changes in beneficial ownership as required under Section 16.

Jennifer L. Davis, elencata come CEO - Health Care presso Procter & Gamble (PG), ha riportato operazioni datate 10/01/2025. Il Modulo 4 mostra una cessione di 64,990.9326 azioni ordinarie e una detenzione indiretta di 15,535.3029 azioni detenute da un fiduciario di un piano pensionistico. La compilazione riporta anche l'acquisizione di 68,869 opzioni su azioni ad un prezzo di esercizio di $153.18; tali opzioni sono indicate come esercitabili a partire dal 29/09/2028 con una data di scadenza 01/10/2035.

Il modulo include una nota esplicativa secondo cui l'importo indiretto riflette un adeguamento al trust di servizio partecipante fino al 30/09/2025. Il documento è firmato a nome della Signora Davis da un procuratore ad acta in data 02/10/2025. Tutti gli elementi riportati sono variazioni di proprietà beneficiaria come previsto dalla Sezione 16.

Jennifer L. Davis, listada como CEO - Health Care en Procter & Gamble (PG), reportó transacciones con fecha 01/10/2025. El Formulario 4 indica una disposición de 64,990.9326 acciones ordinarias y una tenencia indirecta de 15,535.3029 acciones mantenidas por un fiduciario de un plan de jubilación. El archivo también reporta una adquisición de 68,869 opciones sobre acciones a un precio de ejercicio de $153.18; esas opciones figuran como ejercitables a partir del 29/09/2028 con una fecha de vencimiento de 01/10/2035.

El formulario incluye una nota explicativa de que el monto indirecto refleja un ajuste al trust de servicio participante hasta el 30/09/2025. El documento está firmado en nombre de la Sra. Davis por un mandatario (attorney-in-fact) en la fecha 02/10/2025. Todos los ítems reportados son cambios en la propiedad beneficiosa según lo requerido por la Sección 16.

제니퍼 L. 데이비스Procter & Gamble (PG)CEO - Health Care로 등재되어 있으며 2025/10/01자 거래를 보고했습니다. Form 4는 일반 주식의 처분 64,990.9326주와 연금 계획 수탁자가 보유한 간접 보유 15,535.3029주를 보여줍니다. 또한 행사 가격이 $153.1868,869주의 주식 옵션을 취득한 것으로 보고합니다; 이 옵션은 2028/09/29부터 행사 가능하며 만료일은 2035/10/01입니다.

양식에는 간접 금액이 2025년 9월 30일까지 참가자 서비스 트러스트에 대한 조정을 반영한다는 설명 메모가 포함되어 있습니다. 문서는 2025년 10월 2일에 Davis 양의 대리인에 의해 서명되었습니다. 보고된 모든 항목은 제16조에 따라 이익 소유의 변경 사항입니다.

Jennifer L. Davis, nommée CEO - Health Care chez Procter & Gamble (PG), a déclaré des transactions datées du 01/10/2025. Le formulaire 4 indique une cession de 64 990,9326 actions ordinaires et une détention indirecte de 15 535,3029 actions détenues par unfiduciaire d'un plan de retraite. Le dossier indique également l'acquisition de 68 869 options d'achat à un prix d'exercice de $153.18 ; ces options sont indiquées comme exerçables à partir du 29/09/2028 avec une date d'expiration au 01/10/2035.

Le formulaire comprend une note explicative indiquant que le montant indirect reflète un ajustement du trust de service des participants jusqu'au 30/09/2025. Le document est signé au nom de Mme Davis par un mandataire en fait le 02/10/2025. Tous les éléments reportés constituent des changements de propriété bénéficiaire tels que requis par la Section 16.

Jennifer L. Davis, aufgeführt als CEO - Health Care bei Procter & Gamble (PG), hat Transaktionen mit dem Datum 01.10.2025 gemeldet. Das Formular 4 zeigt eine Veräußerung von 64.990,9326 Stammaktien und eine indirekte Beteiligung von 15.535,3029 Aktien, gehalten von einem Treuhänder eines Rentenplans. Das Filing meldet außerdem den Erwerb von 68.869 Aktienoptionen zu einem Ausübungspreis von $153.18; diese Optionen sind mit Ausübungsbeginn am 29.09.2028 und einer Laufzeit bis zum 01.10.2035 aufgeführt.

Das Formular enthält eine erläuternde Anmerkung, dass der indirekte Betrag eine Anpassung des Teilnehmer-Service-Trust bis zum 30.09.2025 widerspiegelt. Das Dokument ist im Namen von Frau Davis von einem Bevollmächtigten unterzeichnet am 02.10.2025. Alle gemeldeten Posten stellen Änderungen des begünstigten Eigentums dar, wie in Abschnitt 16 vorgeschrieben.

Jennifer L. Davis، المدرجة كـ الرئيس التنفيذي - الرعاية الصحية في Procter & Gamble (PG)، أبلغت عن معاملات مؤرخة في 01/10/2025. يظهر النموذج 4 تصرفًا في 64,990.9326 سهماً من الأسهم العادية وامتلاكاً غير مباشر لـ 15,535.3029 سهماً مملوكة من قبل trustee لصندوق تقاعد. كما يُبلغ عن اكتساب 68,869 خياراً للأسهم بسعر ممارسة قدره $153.18؛ تُدرج تلك الخيارات قابلة للممارسة ابتداءً من 29/09/2028 وتاريخ انتهاء في 01/10/2035. يحتوي النموذج أيضًا على ملاحظة تفسيرية تفيد بأن المبلغ indirect يعكس تعديلًا لصندوق خدمة المشاركين حتى 30/09/2025. تم توقيع المستند نيابة عن السيدة ديفيس من قبل محامٍ وكيل في تاريخ 02/10/2025. كل العناصر المبلغ عنها هي تغييرات في الملكية المستفاد منها حسب القسم 16.

Jennifer L. Davis,在 Procter & Gamble (PG) 担任 CEO - Health Care,报道日期为 2025/10/01 的交易。Form 4 显示普通股的 处置 64,990.9326 股,以及由退休计划受托人直接持有的 15,535.3029 股的间接持有。申报还报告了以 $153.18 的行使价购买的 68,869 股股票期权;这些期权列为自 2028/09/29 起可行使,到期日为 2035/10/01。该表还包含一项解释性说明,表明该间接金额反映直至 2025/09/30 的参与者服务信托的调整。文件代表 Davis 女士由一名代理人于 2025/10/02 签署。所有报告项均为按第16条规定的有益所有权变动。

Positive
  • 68,869 stock options acquired at $153.18, providing long-term equity alignment
  • Indirect holding of 15,535.3029 shares retained via a retirement plan trustee
Negative
  • Direct disposition of 64,990.9326 common shares on 10/01/2025
  • Form does not state reason for the share sale, limiting context for investors

Insights

Insider reported a significant share disposition and retained indirect holdings.

The Form 4 records a disposition of 64,990.9326 common shares on 10/01/2025 while still showing an indirect stake of 15,535.3029 shares via a retirement plan trustee. This split between direct sale and indirect retention is common when executives participate in firm-sponsored plans.

The filing is properly signed by an attorney-in-fact on 10/02/2025, and includes an adjustment note tied to the participant service trust through 09/30/2025, indicating administrative reconciliation rather than an undisclosed transaction.

Executive received a sizable option award with long-term vesting window.

The reporting shows acquisition of 68,869 stock options at an exercise price of $153.18, exercisable from 09/29/2028 and expiring 10/01/2035. Such options create potential long-term equity upside for the executive linked to future share performance.

The simultaneous sale of common shares and receipt of options can reflect routine portfolio rebalancing or compensation realization; the document does not state the reason for the sale.

Jennifer L. Davis, elencata come CEO - Health Care presso Procter & Gamble (PG), ha riportato operazioni datate 10/01/2025. Il Modulo 4 mostra una cessione di 64,990.9326 azioni ordinarie e una detenzione indiretta di 15,535.3029 azioni detenute da un fiduciario di un piano pensionistico. La compilazione riporta anche l'acquisizione di 68,869 opzioni su azioni ad un prezzo di esercizio di $153.18; tali opzioni sono indicate come esercitabili a partire dal 29/09/2028 con una data di scadenza 01/10/2035.

Il modulo include una nota esplicativa secondo cui l'importo indiretto riflette un adeguamento al trust di servizio partecipante fino al 30/09/2025. Il documento è firmato a nome della Signora Davis da un procuratore ad acta in data 02/10/2025. Tutti gli elementi riportati sono variazioni di proprietà beneficiaria come previsto dalla Sezione 16.

Jennifer L. Davis, listada como CEO - Health Care en Procter & Gamble (PG), reportó transacciones con fecha 01/10/2025. El Formulario 4 indica una disposición de 64,990.9326 acciones ordinarias y una tenencia indirecta de 15,535.3029 acciones mantenidas por un fiduciario de un plan de jubilación. El archivo también reporta una adquisición de 68,869 opciones sobre acciones a un precio de ejercicio de $153.18; esas opciones figuran como ejercitables a partir del 29/09/2028 con una fecha de vencimiento de 01/10/2035.

El formulario incluye una nota explicativa de que el monto indirecto refleja un ajuste al trust de servicio participante hasta el 30/09/2025. El documento está firmado en nombre de la Sra. Davis por un mandatario (attorney-in-fact) en la fecha 02/10/2025. Todos los ítems reportados son cambios en la propiedad beneficiosa según lo requerido por la Sección 16.

제니퍼 L. 데이비스Procter & Gamble (PG)CEO - Health Care로 등재되어 있으며 2025/10/01자 거래를 보고했습니다. Form 4는 일반 주식의 처분 64,990.9326주와 연금 계획 수탁자가 보유한 간접 보유 15,535.3029주를 보여줍니다. 또한 행사 가격이 $153.1868,869주의 주식 옵션을 취득한 것으로 보고합니다; 이 옵션은 2028/09/29부터 행사 가능하며 만료일은 2035/10/01입니다.

양식에는 간접 금액이 2025년 9월 30일까지 참가자 서비스 트러스트에 대한 조정을 반영한다는 설명 메모가 포함되어 있습니다. 문서는 2025년 10월 2일에 Davis 양의 대리인에 의해 서명되었습니다. 보고된 모든 항목은 제16조에 따라 이익 소유의 변경 사항입니다.

Jennifer L. Davis, nommée CEO - Health Care chez Procter & Gamble (PG), a déclaré des transactions datées du 01/10/2025. Le formulaire 4 indique une cession de 64 990,9326 actions ordinaires et une détention indirecte de 15 535,3029 actions détenues par unfiduciaire d'un plan de retraite. Le dossier indique également l'acquisition de 68 869 options d'achat à un prix d'exercice de $153.18 ; ces options sont indiquées comme exerçables à partir du 29/09/2028 avec une date d'expiration au 01/10/2035.

Le formulaire comprend une note explicative indiquant que le montant indirect reflète un ajustement du trust de service des participants jusqu'au 30/09/2025. Le document est signé au nom de Mme Davis par un mandataire en fait le 02/10/2025. Tous les éléments reportés constituent des changements de propriété bénéficiaire tels que requis par la Section 16.

Jennifer L. Davis, aufgeführt als CEO - Health Care bei Procter & Gamble (PG), hat Transaktionen mit dem Datum 01.10.2025 gemeldet. Das Formular 4 zeigt eine Veräußerung von 64.990,9326 Stammaktien und eine indirekte Beteiligung von 15.535,3029 Aktien, gehalten von einem Treuhänder eines Rentenplans. Das Filing meldet außerdem den Erwerb von 68.869 Aktienoptionen zu einem Ausübungspreis von $153.18; diese Optionen sind mit Ausübungsbeginn am 29.09.2028 und einer Laufzeit bis zum 01.10.2035 aufgeführt.

Das Formular enthält eine erläuternde Anmerkung, dass der indirekte Betrag eine Anpassung des Teilnehmer-Service-Trust bis zum 30.09.2025 widerspiegelt. Das Dokument ist im Namen von Frau Davis von einem Bevollmächtigten unterzeichnet am 02.10.2025. Alle gemeldeten Posten stellen Änderungen des begünstigten Eigentums dar, wie in Abschnitt 16 vorgeschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Davis Jennifer L.

(Last) (First) (Middle)
1 PROCTER & GAMBLE PLAZA

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PROCTER & GAMBLE Co [ PG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO - Health Care
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 64,990.9326 D
Common Stock 15,535.3029(1) I By Retirement Plan Trustee
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $153.18 10/01/2025 A 68,869 09/29/2028 10/01/2035 Common Stock 68,869 $0 68,869 D
Explanation of Responses:
1. Reflects adjustment to PST through September 30, 2025.
/s/ Wednesday Shipp, attorney-in-fact for Jennifer L. Davis 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Procter & Gamble insider Jennifer L. Davis report on Form 4 (PG)?

The Form 4 shows a disposition of 64,990.9326 common shares and acquisition of 68,869 stock options at an exercise price of $153.18, dated 10/01/2025.

How many shares does Jennifer L. Davis indirectly own according to the filing?

The filing reports an indirect beneficial ownership of 15,535.3029 shares held by a retirement plan trustee.

What are the key terms of the options reported on the Form 4 for PG?

The options number 68,869 with an exercise price of $153.18, exercisable from 09/29/2028 and expiring 10/01/2035.

When were these transactions and the Form 4 signature dated?

Transactions are dated 10/01/2025 and the Form 4 is signed by attorney-in-fact on 10/02/2025.

Does the Form 4 explain the indirect share amount?

Yes. The filing states it "reflects adjustment to PST through September 30, 2025."
Procter & Gamble

NYSE:PG

PG Rankings

PG Latest News

PG Latest SEC Filings

PG Stock Data

355.87B
2.34B
0.07%
70.21%
0.74%
Household & Personal Products
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
Link
United States
CINCINNATI